A Phase 1 Dose Escalation Study of Milademetan in Combination with 5-Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

被引：4
|
作者：
DiNardo, Courtney D. [1 ]
Olin, Rebecca [2 ]
Ishizawa, Jo [1 ]
Sumi, Hiroyuki [3 ]
Xie, Jingdong [4 ]
Kato, Kazunobu [4 ]
Kumar, Prasanna [4 ]
Andreeff, Michael [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Calif San Francisco, Hellen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
[3] Daiichi Sankyo Co Ltd, Tokyo, Japan
[4] Daiichi Sankyo Inc, Basking Ridge, NJ USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-122241
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3932
引用
收藏
页数：4
相关论文
共 50 条
  • [31] SINGLE CENTRE SURVIVAL OUTCOMES IN THE TREATMENT OF INTERMEDIATE AND HIGH-RISK MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKAEMIA WITH 5-AZACITIDINE
    Stringer, R.
    Rider, D. T.
    Newman, D. J.
    Grace, D. R.
    [J]. HAEMATOLOGICA, 2015, 100 : 725 - 726
  • [32] PHASE I/II STUDY OF VOSAROXIN AND DECITABINE IN NEWLY DIAGNOSED OLDER PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML) AND HIGH-RISK MYELODYSPLASTIC SYNDROME (MDS)
    Daver, N.
    Kantarjian, H.
    Garcia-Manero, G.
    Jabbour, E.
    Borthakur, G.
    Pierce, S.
    Vaughan, K.
    Vaughan, K.
    Ning, J.
    Gonzalez, G.
    Pemmarjau, N.
    Kadia, T.
    Konopleva, M.
    Andreeff, M.
    DiNardo, C.
    Cortes, J.
    Ward, R.
    Craig, A.
    Ravandi, F.
    [J]. HAEMATOLOGICA, 2016, 101 : 187 - 188
  • [33] Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
    Borate, Uma
    Esteve, Jordi
    Porkka, Kimmo
    Knapper, Steve
    Vey, Norbert
    Scholl, Sebastian
    Garcia-Manero, Guillermo
    Wermke, Martin
    Janssen, Jeroen
    Traer, Elie
    Chua, Chong Chyn
    Narayan, Rupa
    Tovar, Natalia
    Kontro, Mika
    Ottmann, Oliver
    Sun, Haiying
    Longmire, Tyler
    Szpakowski, Sebastian
    Liao, Serena
    Patel, Anuradha
    Rinne, Mikael L.
    Brunner, Andrew
    Wei, Andrew H.
    [J]. BLOOD, 2019, 134
  • [34] A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia
    Cahill, Kirk E.
    Karimi, Yasmin H.
    Karrison, Theodore G.
    Jain, Nitin
    Green, Margaret
    Weiner, Howard
    Fulton, Noreen
    Kadri, Sabah
    Godley, Lucy A.
    Artz, Andrew S.
    Liu, Hongtao
    Thirman, Michael J.
    Le Beau, Michelle M.
    McNerney, Megan E.
    Segal, Jeremy
    Larson, Richard A.
    Stock, Wendy
    Odenike, Olatoyosi
    [J]. BLOOD ADVANCES, 2020, 4 (04) : 599 - 606
  • [35] Phase I dose-escalation study of milademetan in patients with relapsed or refractory acute myeloid leukemia
    Naohiro Sekiguchi
    Senji Kasahara
    Toshihiro Miyamoto
    Toru Kiguchi
    Hitoshi Ohno
    Taiga Takagi
    Masaya Tachibana
    Hiroyuki Sumi
    Yasuyuki Kakurai
    Tomonari Yamashita
    Kensuke Usuki
    [J]. International Journal of Hematology, 2023, 117 : 68 - 77
  • [36] ASSESSMENT OF INFECTION EVENTS IN AZACITIDINE (AZA) TREATMENT FOR MYELODYSPLASTIC SYNDROME (MDS) AND ACUTE MYELOID LEUKEMIA (AML). A SINGLE CENTRE EXPERIENCE.
    Romero, P.
    Borras, J. B.
    Serra, F.
    Nigorra, M.
    Del Campo, R.
    Cladera, A.
    Vazquez, I.
    Mascaro, M.
    Gonzalez, E.
    Guerra, J. M.
    Gomez, D.
    Bargay, J.
    [J]. HAEMATOLOGICA, 2014, 99 : 196 - 196
  • [37] INFECTIOUS COMPLICATIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES/ACUTE MYELOID LEUKEMIA TREATED WITH 5-AZACITIDINE
    Ramos, S.
    Santos, M.
    Tenreiro, R.
    Pereira, M.
    Cortesao, E.
    Rito, L.
    Ribeiro, M. L.
    [J]. HAEMATOLOGICA, 2015, 100 : 474 - 475
  • [38] Phase I dose-escalation study of milademetan in patients with relapsed or refractory acute myeloid leukemia
    Sekiguchi, Naohiro
    Kasahara, Senji
    Miyamoto, Toshihiro
    Kiguchi, Toru
    Ohno, Hitoshi
    Takagi, Taiga
    Tachibana, Masaya
    Sumi, Hiroyuki
    Kakurai, Yasuyuki
    Yamashita, Tomonari
    Usuki, Kensuke
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2023, 117 (01) : 68 - 77
  • [39] Lenalidomide and Risk of Acute Myeloid Leukemia (AML) Transformation Among Myelodysplastic Syndrome (MDS) Patients
    Rollison, Dana E.
    Shain, Kenneth H.
    Lee, Ji-Hyun
    Hampras, Shalaka S.
    Fulp, William
    Fisher, Kate
    Al Ali, Najla H.
    Padron, Eric
    Lancet, Jeffrey
    Xu, Qiang
    Knight, Robert D.
    List, Alan F.
    Dalton, William
    Komrokji, Rami
    [J]. BLOOD, 2014, 124 (21)
  • [40] Phase I evaluation of tipifarnib in combination with low-dose Ara-C (LDAC) in high-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML): Interim results
    Cortes, J. E.
    Feldman, E. J.
    Douer, D.
    Raza, A.
    Fruchtman, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345